To better understand the biology of AD and to identify protein markers of disease, we applied quantitative techniques to identify differential Stratum Corneum (SC) proteins from adult AD patients and normal individuals. Using discovery proteomics we identified over 1000 proteins in the SC, with over 200 differentially identified by condition. Selected proteins were quantified with precise targeted methods. Technical details are described in the Supplementary Materials and Methods (online).
Specifically, we profiled skin surface tape strip samples from 11 AD subjects at lesional and nonlesional sites. These were compared with similar samples from 17 healthy subjects. Combining all spectral evidence, we identified 1102 proteins at a 1% false positive error rate (FPER). This represents the most comprehensive proteomic study of AD stratum corneum to date (Broccardo et al., 2011 , Sakabe et al., 2014 . The full identification list can be found in Supplementary File S1.
A poorly characterized aspect of skin biology is the role of protein post-translational modifications which are abundant in the outer layers of the epidermis. One such is modification is citrullination (conversion of arginine to citrulline, also called deimination) (Gyorgy et al., 2006) . We included citrullination in our search parameters and filtered the results to avoid false positives. We detected at least one citrullination site on 1005 proteins (91% of those identified). The most citrullinated proteins were trichohyalin and filaggrin, which are known to be heavily modified in vivo. For filaggrin, healthy and nonlesional atopic skin were citrullinated on 78% and 75% of arginine residues, respectively. This decreased to 62% in lesional skin, corresponding to a loss of modification on 56 residues. Of the 386 proteins that were citrullinated in all conditions, 257 exhibit decreased fractional citrullination in lesional sites compared to other conditions (Figure 1 ). Notably, trichohyalin, an abundant hair protein not considered related to AD, showed a negligible difference by the same comparison.
We next analyzed differential proteins by two methods: Fisher's exact test on identification counts by condition and Student's t-test on label-free quantification results for proteins observed in greater than 10 samples ( Figure 2B ). These include inflammation-related proteins such as serpins A1, B3, & B12 and S100s A8, A9, and A11. Proteins down-regulated in AD skin are generally structural, including several keratins as well as filaggrin-2. Fillagrin-2 was only annotated in 2009 (Wu et al., 2009 ) and mutations have been recently linked to persistent AD (Margolis et al., 2014) . When comparing nonlesional and lesional AD samples, 45 proteins are differentially observed (Figure 2A & Supplementary File S1) . 16 are preferentially found at the lesional site while 29 are observed more frequently in nonlesional samples. The protein most preferentially identified at the lesional site was PYCARD, a key regulator of inflammasome and activation and apoptosis (Martinon et al., 2002) . One protein found at the majority of nonlesional sites but only at 9% of lesional sites was SPINK5, a gene with mutations linked to AD in Japanese patients (Kato et al., 2003) .
To confirm results from discovery LC-MS/MS, we targeted several AD-related proteins using more sensitive and precise Selected Reaction Monitoring (SRM) mass spectrometrybased assays. These results support our shotgun LC-MS/MS label-free quantification, but with increased sensitivity as expected. Caspase 14, beta-defensin, desmoglein-1, desmoplakin, filaggrin, kallikrein-8, keratin 10, S100-A7, and S100-A9 all increase when comparing healthy to atopic nonlesional skin. In addition, beta-defensin, filaggrin, S100-A7, and S100-A9 further increase from nonlesional to lesional atopic skin. The only targeted protein to show a significant decline is filaggrin-2, which decreases substantially from nonlesional compared to lesional epidermis, in agreement with label-free quantification above. Given the evidence for reduced abundance of filaggrin in atopic dermatitis from several studies (Suarez-Farinas et al., 2011 , Pellerin et al., 2013 , our observation of increased SRM signal in atopic skin may seem counterintuitive. Our label-free quantification found filaggrin to be similar between healthy and AD (p=0.2, supplementary file S1). It is important to consider that in the targeted SRM assay we are monitoring SRM signal from the fully tryptic unmodified peptide, 3976 HGSYGSADYDYGESGFR 3992 . In addition to the mass shift introduced by citrullination, we observed that this modification typically results in a missed cleavage at arginine, rendering the peptide invisible to the SRM assay deployed here. Thus our observation is consistent with decreased citrullination on the endogenous peptide as disease progresses. Indeed, the majority of evidence for filaggrin protein loss comes from immunohistochemistry experiments where antibody epitopes are not always characterized. It is possible that these epitopes are citrullinated, similar to those observed in vivo for rheumatoid arthritis (Girbal-Neuhauser et al., 1999) .
While genetic factors tied to AD have been investigated in some detail, these account for a minority of disease incidence (Baurecht and Hotze, 2015) . Much focus has been directed toward filaggrin loss-of-function mutations, however transcriptomic profiles stratified by filaggrin mutation status demonstrate an up-regulation of this protein in wild-type AD patients (Cole et al., 2014) . We find a modest overlap between transcript and proteomic differential markers (Supplementary information). Non-genetic potential disease factors including microbiome diversity and epigenetic factors like DNA methylation have only recently begun to be investigated (Kong et al., 2012 , Rodriguez et al., 2014 . The data presented here demonstrate alterations in the protein post-translational modification profile of patients with AD lesions which ultimately adds another dimension to the rich and complex etiology of AD.
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